Abstract: The disclosure relates to compounds, compositions, methods and uses relating to activation of one or more serotonin receptors (i.e., 5-HT2 receptors). Specifically, the disclosure provides ester derivatives of psilocin and related tryptamines, and methods for treating neurological diseases or disorders, including neurodegenerative diseases, pain, and/or psychiatric disorders that comprise the compounds or compositions thereof. Also provided are methods for preparing the compounds described herein.

Abstract: This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.

Abstract: This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

Abstract: The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

Abstract: This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in the treatment or prevention of a disease associated with a cannabinoid receptor, including receptors selected from CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPAR? or a ?-opioid receptor.